From the midfacial destructive drama to the unfolding EBV story: a short history of EBV-positive NK-cell and T-cell lymphoproliferative diseases

Pathology. 2024 Oct;56(6):773-785. doi: 10.1016/j.pathol.2024.07.002. Epub 2024 Jul 25.

Abstract

Epstein-Barr virus (EBV) is a ubiquitous gammaherpesvirus that has been related to oncogenesis of lymphoid and epithelial malignancies. Although the mechanism of EBV infection of NK and T cells remains enigmatic, it plays a pathogenic role in various EBV+ NK-cell and T-cell lymphoproliferative diseases (LPDs), through promotion of cell activation pathways, inhibition of cell apoptotic pathways, behaving as oncogenes, interacting with host oncogenes or acting epigenetically. The study of NK-cell LPDs, previously hampered by the lack of immunophenotypical and genotypical criteria of NK cells, has become feasible with the recently accepted criteria. EBV+ NK- and T-cell LPDs are mostly of poor prognosis. This review delivers a short history from primeval to recent EBV+ NK- and T-cell LPDs in non-immunocompromised subjects, coupled with increasing interest, and work on the biological and oncogenic roles of EBV.

Keywords: EBV-positive; NK-cell lymphoproliferative diseases; T-cell lymphoproliferative diseases; non-immunocompromised.

Publication types

  • Review

MeSH terms

  • Epstein-Barr Virus Infections* / complications
  • Epstein-Barr Virus Infections* / immunology
  • Epstein-Barr Virus Infections* / virology
  • Herpesvirus 4, Human* / immunology
  • Humans
  • Killer Cells, Natural* / immunology
  • Killer Cells, Natural* / pathology
  • Killer Cells, Natural* / virology
  • Lymphoproliferative Disorders* / immunology
  • Lymphoproliferative Disorders* / pathology
  • Lymphoproliferative Disorders* / virology
  • T-Lymphocytes* / immunology
  • T-Lymphocytes* / pathology